Investindustrial and HTL-Strefa S.A.

Go to content

Investindustrial and HTL-Strefa S.A.

Wardyński & Partners advised Investindustrial on its acquisition of HTL-Strefa S.A. from EQT.

Investindustrial acquired the entire share capital of HTL-Strefa S.A. (“HTL”), a renowned Polish med-tech company, from EQT.

Formed in 1994, HTL is a leading global medical technology company that develops, manufactures and sells blood-micro sampling and drug injection devices.

Founded in 1990, Investindustrial is one of Europe’s leading independent investment groups focused on taking control positions predominantly in Southern European medium-sized companies that are leaders in their fields. Its current portfolio includes, among others, Artsana, Aston Martin and Sergio Rossi.

Following the acquisition, HTL will merge with PIC, Artsana’s Healthcare business acquired by Investindustrial in 2016. The merger of Artsana’s consumer health business with HTL will result in an international player to better serve customers and partners in diabetes management and self-care devices, offering a full spectrum of highly specialised diabetes management devices across consumer and professional healthcare channels with sales in more than 100 countries and 1,800 employees.

Advisors on the transaction for Investindustrial were: Studio Chiomenti and Wardyński & Partners (legal), McKinsey (business), Lazard (financial), PWC (accounting), Willis (insurance) and Golder Associates (environmental).

Wardyński & Partners advised on Polish aspects of the transaction, including due diligence, tax, financing, share transfer, closing and post-closing actions.